PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) saw a large growth in short interest in July. As of July 31st, there was short interest totaling 429,834 shares, a growth of 113.0% from the July 15th total of 201,780 shares. Based on an average daily trading volume, of 146,360 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1,074.6% of the shares of the company are short sold.

Institutional Investors Weigh In On PicoCELA

A hedge fund recently bought a new position in PicoCELA stock. XTX Topco Ltd acquired a new stake in shares of PicoCELA Inc. (NASDAQ:PCLA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA at the end of the most recent quarter.

PicoCELA Stock Up 6.6%

PCLA stock traded up $0.42 during trading on Friday, reaching $6.76. The stock had a trading volume of 265,414 shares, compared to its average volume of 357,809. PicoCELA has a 52 week low of $1.35 and a 52 week high of $19.61. The stock’s 50 day moving average is $5.41 and its two-hundred day moving average is $4.32.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PCLA. Weiss Ratings downgraded shares of PicoCELA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 3rd. Wall Street Zen raised shares of PicoCELA to a “hold” rating in a report on Saturday, July 25th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.